Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.48 |
| ▸ | FAP | Q12884 | 5/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
| ▸ | PITRM1 | Q5JRX3 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8214179 | 0.82 | PREP (0.39) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL8288249 | 0.82 | ALDH1A1 (0.41) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL13372095 | 0.82 | PREP (0.37) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL8288240 | 0.81 | DPP4 (0.55) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL13347238 | 0.80 | DPP4 (0.49) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL13347236 | 0.79 | DPP4 (0.53) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL13347239 | 0.79 | DPP4 (0.50) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL13347235 | 0.77 | DPP4 (0.64) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL8288248 | 0.77 | MEN1 (0.48) | DPP4DPP9DPP7FAPDPP8 | |
| SCHEMBL8214993 | 0.71 | PREP (0.39) | DPP4DPP9DPP7FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1997533-A1 | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | Phenomix Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070185061-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | PHENOMIX CORPORATION | 2007-08-09 | — | — | US | disclosed |
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | PHENOMIX CORPORATION | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | DPP4, DPP7, DPP3 | DPP4 1/4885DPP9 6/4885DPP7 2/4885 |
| US-20070185061-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | DPP4, DPP7, DPP3 | DPP4 1/4885DPP9 5/4885DPP7 2/4885 |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP9 7/4885DPP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.